Latest / The BioHub - by Avetix / Episode 153 - Lan Huang - CEO of SEED Therapeutics

Transcript

Episode 153 - Lan Huang - CEO of SEED Therapeutics · The BioHub - by Avetix

• 0:06
  So welcome back to another episode of the Bio Hub.
• 0:08
  Today we're delighted to welcome on LAN Huang, who's the Co
• 0:12
  founder, CEO and Chairman of Seed Therapeutics, accompanied
• 0:15
  at the forefront of targeted protein degradation.
• 0:18
  Under her leadership, Seed has been building a platform
• 0:21
  designed to unlock some of the toughest targets in cancer and
• 0:24
  other serious diseases. Land's journey started in the
• 0:27
  lab, earning her PhD in Chemistry from UC Berkeley and
• 0:31
  conducting research at Memorial Sloan Kettering Cancer Centre,
• 0:35
  as well as becoming a serial entrepreneur found in multiple
• 0:38
  biotech companies and taking Beyond Spring Pharmaceuticals
• 0:42
  public whilst advancing innovative oncology therapies
• 0:46
  into late stage development. So join us today as we'll
• 0:49
  discuss the TPD space, the science behind the lead program
• 0:54
  and the and the biggest challenges in getting seed to
• 0:56
  where it is today. So Lam, thanks so much for
• 0:59
  coming on. How are you?
• 1:01
  Very good. Thanks for this rare opportunity
• 1:04
  and thanks for giving us the time to share my personal
• 1:08
  journey and also seeds journey to develop transforming medicine
• 1:14
  for patients and also to have positive impact in human human
• 1:19
  diseases. Well, look, it's a pleasure to
• 1:21
  have you on that. Let's just start off with a
• 1:22
  little bit about your journey through the field and, and how
• 1:25
  you got to where you are today. So can you just talk us through
• 1:28
  that journey in life sciences and drug discovery?
• 1:31
  What was the, oh, I'd love to hear what first sparked your
• 1:34
  interest in science and the path that led you into biotech?
• 1:37
  And how did some of your earlier experiences shape the direction
• 1:40
  that your career ultimately took?
• 1:42
  Well, thanks for this weak question.
• 1:45
  So actually my journey into biotech started from a personal
• 1:49
  note. When I was young, I was raised
• 1:53
  by my grandparents in Shanghai, so my grandpa actually died of
• 1:58
  liver cancer when I was nine years old.
• 2:01
  At that time, it was a devastating event for me and I
• 2:05
  really wanted to help him, you know, and the other, you know,
• 2:10
  loved ones. So that was a little bit seed in
• 2:14
  my heart. So I want to learn how to
• 2:17
  develop medicine to help other grandparents so that they
• 2:22
  wouldn't suffer, you know, from their family members.
• 2:26
  So that was the initial personal seed.
• 2:29
  And later, as you just mentioned, I was educated in
• 2:34
  good institutions, including UC Berkeley and also MSK.
• 2:40
  So I learned a lot in Cancer Research and very importantly,
• 2:46
  when I was at MSKII did solve the 1st E3 ligase structure,
• 2:52
  which was a science paper. And from there on I saw it, you
• 2:56
  know, a structure is just a pretty picture.
• 2:59
  It will be very helpful if I can develop medicine from the
• 3:03
  discovery I generated. So that's all I started being
• 3:08
  entrepreneur. So afterwards I have build and
• 3:12
  so companies to Whopper Pinkas to Shanghai Pharmaceutical Group
• 3:16
  and also brought Beyond Spring public a very, very you know
• 3:21
  heartwarming event at the Beyond Spring is we we have been
• 3:25
  developing a late stage first in class immuno oncology agent
• 3:30
  called plinabulin so it can treat late stage non small cell
• 3:34
  lung cancer. So in our phase three study,
• 3:37
  doubling 3, we had treated, you know, many patients globally,
• 3:41
  one specific patient and her name is Margaret from Australia.
• 3:47
  So she actually had used many drugs before in, you know, as a
• 3:53
  non sports a lung cancer patient.
• 3:55
  But she failed everything including the important PD one
• 3:59
  agent. So at end of the study she
• 4:02
  actually wrote us a thank you letter.
• 4:05
  She said that because of plinabulin, she got to live to
• 4:10
  see two of her grandchildren being born.
• 4:14
  So that was so heartwarming because I couldn't help my
• 4:18
  grandpa, but the drug we are developing are helping other
• 4:23
  grandparents. So this is truly a homecoming
• 4:27
  and heartwarming event for me. I love that there's a personal
• 4:31
  touch behind that as well. Let's just talk about the
• 4:34
  origins of C Therapeutics. What what was the initial idea
• 4:38
  or scientific insight that let's the founding of the company and
• 4:42
  how did that idea revolve into a a full biotech venture and and
• 4:47
  started a new company? Yes, thank you for this
• 4:50
  insightful question. So as you see that EY E33, the
• 4:56
  building system was discovered almost 50 years ago by Doctor
• 5:00
  Hirschko at the Nobel Prize winner.
• 5:03
  And afterwards there was a proteasome inhibitor being made
• 5:09
  in the 2000s. And and then the really
• 5:14
  initiation of our idea of starting seed really come from
• 5:19
  the discovery of a Revlimid which which actually achieved
• 5:24
  top point 8 billion annual cells before they they were it was
• 5:29
  discovered to be a molecular group basically using Easter
• 5:34
  ligase seroblum to degrade transcription factors.
• 5:38
  And then that actually leads to the very effective therapy for
• 5:42
  multiple myeloma. So that was in the 2010 to 2014
• 5:48
  time. So after that I actually
• 5:51
  reunited with my Co founder, Professor Ying Jung from
• 5:55
  University of Washington who actually was trained at the MSK
• 6:00
  lab with me almost 20 years ago. I said, you know, we know the
• 6:04
  East to ligase really well and so why don't we, you know, use
• 6:09
  our knowledge in the East to ligase which actually recognized
• 6:12
  this is protein for degradation to start exploring using or
• 6:18
  knowledge to develop molecule glue treatment.
• 6:22
  So that was in 2015. So it was beyond spring.
• 6:26
  I just started a sponsor research with University of
• 6:30
  Washington. After few years of research,
• 6:34
  we're very fortunate to get a phone call from Eli Lilly
• 6:38
  regarding our research. So after a year and a half of
• 6:42
  due diligence, Sarah Dujin, even during COVID, you know, Lily was
• 6:49
  very happy with what they see. And then we actually Co founded
• 6:54
  C Therapeutics together so and Beyoncé been putting all the
• 6:59
  technology and and Lily putting the initial investment and also
• 7:04
  gave us R&D collaboration which is very important for the
• 7:10
  initiation of of seed. So that was almost five years
• 7:14
  ago. Amazing.
• 7:16
  And the company, it's obviously focused within targeted protein
• 7:19
  degradation, which is it has definitely become one of the
• 7:22
  most exciting areas in drug discovery.
• 7:24
  I know there's been a lot of new companies that have decided to
• 7:27
  set up in, in this particular area.
• 7:30
  What What was it about this emerging field in in TPD that
• 7:34
  convinced you it could fundamentally change how how we
• 7:37
  approach treating diseases? Yeah.
• 7:39
  Thank you for this great question.
• 7:41
  So as you see that you know TPD target protein tubation, they're
• 7:47
  using a new way to eliminate protein, not just inhibit it.
• 7:52
  So molecular glue in the TPD space has the potential of
• 7:57
  targeting 80% of underport target, which includes a protein
• 8:02
  without pocket and also unfolded proteins.
• 8:06
  So that's the potential of this technology.
• 8:11
  And as we, you know, we are good fans of all the other great TPD
• 8:16
  companies and including, you know, Avinas in the initial
• 8:21
  stage and then Camara and Nurex and then also Monty Rosa.
• 8:26
  So all of this you know using this TPD technology to develop
• 8:31
  medicine to really target on trouble target.
• 8:35
  So this is a new modality which could be transforming for
• 8:40
  cancer, that and also other neurodegeneration and many
• 8:43
  different disease areas. That's exciting.
• 8:46
  So you guys are doing something. You mentioned having us and
• 8:49
  Chimerons and and those types of companies.
• 8:52
  So you guys are working on the same type of disease but just in
• 8:55
  a different modality? Yes, I think we have different
• 8:59
  ways of targeting the the diseases.
• 9:03
  So from our seeds differentiation point of view,
• 9:07
  we are target centric. So actually we basic give us any
• 9:12
  protein target or can find the right E3 ligase and also develop
• 9:17
  molecular blue for it. Our leaders that is already in
• 9:21
  clinical studies for oncology. So why give us this confidence
• 9:27
  and the special traits to be able to use a novel E3 ligases
• 9:33
  because out of the 640 E 3 ligases in the cell, there's
• 9:38
  only two structural classes. Why is the heck domain E3 class
• 9:43
  which I solved another is the ring finger E3 class which our
• 9:48
  Co founder professor Ningen soft.
• 9:50
  So you see that we have a really good understanding of all the E3
• 9:55
  ligases in the cell. So we want to change, you know,
• 9:59
  this novel history selection from a biology problem into a
• 10:04
  physics problem. In addition, we have two other
• 10:07
  very important Co founders. 1 is Doctor Hirschko, the Nobel Prize
• 10:12
  winner really started the whole field, so really understanding
• 10:15
  fundamental biology. Another Co founder is Professor
• 10:19
  Michaeli Pagano, who is the head of biochemistry and Monaco
• 10:24
  pharmacology from NYU Medical School, a true pioneer in the
• 10:29
  biology. So all of us together really
• 10:31
  give us the central foundation to target the undruggable
• 10:37
  protein in the unique way. And you, you mentioned on
• 10:40
  college is a, the main therapeutic area that you asked
• 10:44
  and it is, is there a potential to, to span into different areas
• 10:47
  as well, maybe like neuroscience or yeah, it's the potential to
• 10:51
  go to other areas as well. Yes, so you are 100% correct.
• 10:58
  That's why we can target 80%. This is causing protein
• 11:02
  currently not druggable because protein regulations through the
• 11:06
  ubiquitination. Immediate degradation is a
• 11:10
  fundamental biology for regulating protein level and
• 11:14
  that's why it won Nobel Prize because it's general.
• 11:18
  So all the proteins in our cells, they have different
• 11:21
  functions. It could be, you know, involved
• 11:24
  in cell growth and uncontrolled cell growth leads to cancer
• 11:28
  development or, you know, neurodegeneration or immunology
• 11:33
  or a viral, you know, antiviral, you know, agents, right so and
• 11:39
  all or obesity and, and, and the metabolic.
• 11:42
  So because all of the protein is the functional unit in our
• 11:46
  cells, but they do mutate and sometimes they unfold.
• 11:50
  So basically TPD target protein dedication is a fundamental
• 11:56
  regulation way for those proteins.
• 11:59
  That's exciting. And for people who might not yet
• 12:02
  be as familiar with seed therapeutics, could you just
• 12:06
  give us a bit of a deeper overview of the company, you
• 12:08
  know, the mission, the scientific behind, scientific
• 12:11
  vision behind it, and the problem that you're really
• 12:14
  trying to solve as well? So SEED is funded by pioneers in
• 12:21
  the TPD space and why focus on developing molecular glues to
• 12:27
  target protein currently not druggable.
• 12:31
  So our specialty is really target centric.
• 12:34
  So give us any protein of interest and then we will
• 12:38
  develop the right E3. It could be the novel E3 and
• 12:42
  then develop molecular glue for it.
• 12:45
  And so far, we have used our technology and working on six
• 12:50
  key programs, 6 internal and three is with our partner Eli
• 12:55
  Lilly and also a side target multiple indications including
• 13:00
  oncology, neurodegenerial degeneration and also
• 13:04
  immunology. Our lead asset, a novel RBM 79
• 13:08
  degrader is already in clinical study, which is generating
• 13:12
  exciting clinical data as we speak and really targeting a
• 13:16
  very important unjustable target and also for multiple solid
• 13:22
  tumor indications. Amazing.
• 13:27
  You, you mentioned a couple of the partnerships that you have
• 13:29
  already just in terms of your lead program, there's obviously
• 13:32
  been a lot of interest in the field around that.
• 13:35
  Could you just walk us through like the biology behind the
• 13:38
  target? What do you think makes it
• 13:41
  compelling from a from a disease perspective?
• 13:44
  And you mentioned a little bit about the differentiation like,
• 13:47
  yeah, what, what makes it different from maybe other
• 13:49
  companies that that are in this space?
• 13:52
  Yeah, what? What makes it different?
• 13:55
  Well, thank you for this insightful question.
• 13:58
  So our lead program is in RBM 39 and a field.
• 14:03
  So RBM 39 is RNA splicing protein.
• 14:07
  So what it does is as you know and in the RNA space and there's
• 14:12
  intron Axon. So if the intra Axon not cut the
• 14:16
  right way then there will be fusion protein generated.
• 14:19
  So student protein could cause cancer.
• 14:23
  So and we have seen you know conical data showing that over
• 14:28
  expression of RBM 39 actually causes you know patient to to
• 14:34
  have shorter lives including colon cancer and also liver
• 14:39
  cancer and other important solid tumors.
• 14:42
  But another very important indication our RBM 39 degrader
• 14:47
  could go target is O1 sarcoma. So O1 sarcoma is a fusion driven
• 14:53
  cancer which has no targeted or novel drugs for the last 30
• 14:58
  years and then the one of the fusion protein is called EWS 31
• 15:04
  which causes 90% of OWL and sarcoma.
• 15:07
  So our innovative RBM 39 degrader could eliminate RBM 39
• 15:15
  and also the E double S31 in our animal model and also showed
• 15:20
  total tumor regression in our animal model.
• 15:23
  So it's very targeted and not only this is a disease, it's a
• 15:29
  rare disease. However, it does also target
• 15:32
  children. So we believe that, you know,
• 15:35
  our drug not only can really help the solid tumor, probably
• 15:40
  more the adult rumors, but also for some type of cancer for
• 15:45
  children. That's also another very
• 15:47
  important heart heartwarming effect from what we do.
• 15:52
  But on top of that, So discovery wise, it's uses the decal 15,
• 15:58
  which is a novel E3 aside from the VHL and the Sarah blonde,
• 16:07
  which a lot of company are using.
• 16:10
  So and our Co founder, Professor Ninjin has deep knowledge from
• 16:14
  biology and the structural point of view on the decal 15.
• 16:18
  So we really have very insightful view into this RBM 39
• 16:23
  and the Decar 15 complex. That's why we believe that our
• 16:27
  agent could be the best in class in the field.
• 16:30
  So this is on the discovery side.
• 16:32
  Our uniqueness and and also the competitive advantage perform a
• 16:37
  clinical development point of view because in the end you have
• 16:41
  to develop the molecular glue into medicine.
• 16:44
  So we are very, very fortunate and also honored to work with
• 16:49
  leading investigators from the US, including investigators from
• 16:55
  Dano, Faba, Mass General Memorial, Stone Catchering, MD
• 17:01
  Anderson and also City of Hope. So I think was there important
• 17:07
  help so we have a higher chance of bringing our novel agent to
• 17:12
  patients and eventually to NDA? Wow, that's exciting.
• 17:16
  Yeah. I think like someone that saw
• 17:18
  them either side of the fence always get an insight into what
• 17:22
  from a recruiter side of things, always get an insight into like
• 17:24
  what VCs think is an interest interesting space.
• 17:27
  You always hear I and I and obesity and diabetes.
• 17:30
  But yeah, TPD is definitely one of them as well.
• 17:33
  So it sounds like a super interesting time for you guys
• 17:37
  and certainly made a lot of progress as well, which is which
• 17:39
  is super exciting. Yeah, I think it is.
• 17:43
  I think it's it's such a transformative time right now
• 17:46
  from a technology point of view. And I think there is so much
• 17:51
  interest into, you know, many different areas also including
• 17:55
  using AI and to speed up the drug discovery and development
• 18:00
  and also bring in China into the space to increase the speed in
• 18:06
  Canco development and also reduce the cost in development.
• 18:10
  And that also are the two important surround sound we are
• 18:14
  using to develop our medicine in the more time and 'cause
• 18:19
  efficient. Matter and like as you look
• 18:21
  ahead to the next phase of of C therapeutics development, what
• 18:25
  what are the next major milestones for the company over
• 18:27
  the next year or two, whether that's from a scientific or
• 18:31
  clinical or strategic or partnership perspective?
• 18:35
  And and which are you personally most excited about in terms of
• 18:38
  those milestones and and why? Well, thank you for this for
• 18:42
  looking question. So we are very excited about
• 18:46
  where we are at the seat. We believe that 2026 is a value
• 18:51
  infection year for our company because now we have transformed
• 18:57
  ourselves from a preclinical company into a clinical
• 19:00
  development company. So looking forward into the, you
• 19:04
  know, next 12 to 24 months, I can see a few very exciting
• 19:09
  milestones being expected. So #1 is for our novel RBM 79
• 19:16
  and degrader. So in clinical studies.
• 19:18
  So we are projecting Phase 1A data, which includes the safety,
• 19:25
  PKPD and target engagement data and also you know RP2D to, to
• 19:32
  get to the next extension cohort.
• 19:36
  So this is really exciting to really showcase how we can
• 19:40
  develop this really important molecular glue in the precision
• 19:45
  medicine way and working with all the conditions from the US
• 19:49
  and also in, in including China into the whole space to, to
• 19:54
  really get to this efficacy data quicker.
• 19:57
  So, so that's number one. Number two is as we just related
• 20:02
  to TPD is not only for cancer. So we are actually also
• 20:06
  developing oral call degrader for Alzheimer's disease.
• 20:11
  This is. Is a really exciting area where
• 20:13
  also not only we are moving the program forward in the
• 20:18
  meaningful way, we also are receiving great interest from a
• 20:22
  global pharma who potentially could also work with us to speed
• 20:27
  up development of our oral hall degrader.
• 20:31
  So that's the next important, you know milestone.
• 20:35
  And the third one is we because our red E Street platform is
• 20:41
  really the golden goose. So the golden goose can also lay
• 20:45
  a lot of eggs. So currently we're working on
• 20:48
  other golden eggs in the preclinical space.
• 20:51
  So hopefully in the next 12 to 24 months, we will be able to
• 20:55
  have another lead asset to be able to go into the the tree and
• 21:01
  the, you know, a development stage.
• 21:04
  So that can also give, you know, flowers to benefit patients with
• 21:10
  a member called needs. Amazing.
• 21:12
  Sounds so exciting and you moving on, you see you've built
• 21:17
  building any early stage company can be incredibly rewarding, but
• 21:21
  but definitely challenging. You've obviously had experience
• 21:24
  of of doing this before being an entrepreneur and building
• 21:27
  startups out from scratch. What in particular have been
• 21:31
  some of the biggest hurdles you've faced in in getting seed
• 21:35
  to where it is today? From from building from nothing
• 21:37
  to to where it is now? Yeah.
• 21:40
  As an entrepreneur, I think our traits is to be resourceful to
• 21:46
  go from zero to 1, from nothing to something.
• 21:49
  So, so it is truly a challenge. I think 2 important challenge we
• 21:54
  had in the beginning is number 1 is to recruit great people while
• 21:59
  you really don't have much. And the number 2 is raise money,
• 22:03
  right to to be able to realize the vision into something which
• 22:08
  is more tangible. So I think in the end, to
• 22:12
  overcome those challenges, I think it's really to share the
• 22:17
  vision and also to have really the initial great people to be
• 22:23
  at the table. For example, C does have the
• 22:27
  Nobel Prize winner, also The Pioneers in the space.
• 22:30
  And I do have the background of A solving the first Easter Lycas
• 22:34
  in the field and also the biotech entrepreneurial
• 22:38
  background, you know, before I Co founded seed.
• 22:42
  So those are background and initial, you know, nucleus of of
• 22:47
  people actually can shed light into what we do.
• 22:51
  And then I'm very grateful to the initial, you know, recruits
• 22:56
  for the company. And now currently, you know, we
• 22:59
  are together making seed a viable and also exciting
• 23:03
  company. And the secondly, of course, is
• 23:06
  raising money. We're, we're truly, truly very
• 23:11
  grateful to Lily's support. Even though the due diligence
• 23:16
  was long, it was a year and a half due diligence and even
• 23:20
  during COVID time, however you know, after their due diligence,
• 23:25
  they they are brave and then really tackle into this TPD
• 23:30
  space. Especially we are using novel
• 23:32
  histories now using the cell blind VHL people have
• 23:36
  characterized very well. So using novel E3 to tackle
• 23:41
  under 4 targets and then to really open up this new modality
• 23:46
  field takes courage and also conviction.
• 23:51
  So we would truly, you know, are grateful and honored to work
• 23:56
  with Lily and and to make things happen.
• 24:00
  And of course, from our Co founders team, they actually
• 24:02
  started to feel that we better started fields.
• 24:05
  Of course we we are, you know, convinced and and I, but of
• 24:10
  course it takes huge effort and collaboration to be able to
• 24:15
  realize this great dream. Amazing.
• 24:18
  And just talk us through the culture that you've built at At
• 24:22
  Sea Therapeutics as well. I think people is is just as
• 24:26
  important as anything in any early stage company.
• 24:29
  Just talk us through the culture that you have built and trying
• 24:32
  to build it at Sea Therapeutics and why is that such an
• 24:35
  important thing for you? Yes, I believe that every
• 24:39
  company should have soul. So the value system, the culture
• 24:43
  is the soul of the company and in a way we build it together.
• 24:49
  I'm the nucleus and everyone in mind was this culture and also
• 24:55
  this value. So we, we say our company has
• 24:59
  this 4 pillars of value system or culture.
• 25:03
  So #1 we're building a platform for everybody to grow.
• 25:07
  So I think even though, you know, we are all experiencing
• 25:10
  what we do, but we always have something to learn and perfect.
• 25:13
  So we are building this very inviting environment for
• 25:18
  everybody to learn more and grow so they can grow up in our
• 25:22
  ladder or if later they want to go to another company to grow up
• 25:26
  in that ladder. It's a great platform for them.
• 25:28
  So it's really the great soil for the seed to to sprout and,
• 25:33
  and #2 is this is, you know, it's a we we want our team to
• 25:38
  contribute to water the seed to really grow into a little tree
• 25:42
  and the later into this forest. So it's not a one way street.
• 25:47
  So we like our team to really contribute tremendously to to
• 25:52
  the company grows from their previous experience, from their
• 25:55
  resources. So #3 and this is really a home
• 26:00
  away from home. So we build a really respectful
• 26:03
  environment, a collaborative environment for our team members
• 26:07
  and we really treat them as family members to do something
• 26:11
  possible and making impossible into possible.
• 26:14
  So the so the value we have which build for our company is
• 26:19
  first respect number two is fun #3 is quality.
• 26:24
  So always have quality data, quality people, and #4 is
• 26:29
  efficiency. So always have time and cost
• 26:31
  efficiency #5 is perseverance because nothing is easy.
• 26:36
  You have to believe in it and then push it through.
• 26:39
  And #5 is collaboration. So it takes a team to make
• 26:43
  everything happen. So that's number three, right?
• 26:46
  The we're building a home away from home and #4 is very
• 26:51
  important. Where do I'm doing something
• 26:54
  bigger than ourselves. It's not something just for
• 26:58
  ourselves alone, for our own goal.
• 27:00
  It's for mankind. So that's what we're doing.
• 27:04
  So it went developing transform medicine to change impossible
• 27:09
  targets into possible target and which can treat diseases of, you
• 27:15
  know, patients. So so that's that's where we
• 27:18
  are. And those are the four pillars
• 27:21
  of value. That's our culture and our
• 27:23
  smoke. Amazing.
• 27:25
  And you guys all how how does the business work?
• 27:27
  You were an on site company. Do you have people on a hybrid
• 27:31
  you remote? Like how does that work?
• 27:34
  Yeah, see this on site company because we do experiments.
• 27:38
  So we have a 10,000 square feet live space at King of Prussia,
• 27:43
  PA and we'll build it from scratch.
• 27:46
  And people do Kingdom every day to do experiments.
• 27:50
  For sure. And look, this is a question
• 27:52
  that we we always finish with as well.
• 27:54
  And I know I wanted to give you a bit of a heads up because it's
• 27:57
  probably the question might take a little bit more for than
• 27:59
  others. But if you were to sit down and
• 28:02
  have the opportunity to invite any free people from past or
• 28:05
  present for for a dinner, who would you invite and and why?
• 28:10
  That that's a thought provoking question and I will have
• 28:14
  different answers at different age of my life, but in my
• 28:18
  current H and I, I I would, you know, love to invite this three
• 28:25
  very important people. So why is Jennifer Donna?
• 28:29
  The second is Jason Huang and the third is Michael Bloomberg
• 28:35
  to dinner. So because all of them has
• 28:38
  started a new industry and that's solving a very important
• 28:42
  problem against all odds. And what they have achieved
• 28:46
  really bring brought positive impact to society and human
• 28:51
  lives. And let me say things you know,
• 28:55
  one by one say my reasons. So #1 Jennifer Donna.
• 29:00
  So she of course, a woman role model.
• 29:02
  So I'm a woman and she is a structural biologist by training
• 29:07
  and now a professor at UC Berkeley.
• 29:09
  So I'm also a structural biologist.
• 29:11
  And I of course had the PhD from Berkeley.
• 29:14
  But very importantly, she's also the Nobel Prize winner and she
• 29:19
  discovered Crispa. So now she has, you know, Co
• 29:23
  founding many companies which using, you know, Crispa and
• 29:27
  other important technologies really to change people's lives.
• 29:31
  So those are her achievement. But the hard thing is I did read
• 29:36
  her biography, Code Breaker. So that really showed her
• 29:40
  journey into this, you know, biotech ward.
• 29:44
  So when she started Co founding companies after she was already
• 29:48
  a Nobel Prize winner, nobody gave her money.
• 29:52
  She had to raise money from SPR from the government like some of
• 29:57
  them just started with 200,000 to initiate.
• 30:00
  But against all odds, of course, now you know, raising money for
• 30:05
  her is is not the issue, but she really start from the humble
• 30:08
  beginning and not getting any any money from investors, right.
• 30:13
  So, so I think that give me a little bit, you know,
• 30:18
  perspective in my challenge, in our challenge in, in raising
• 30:23
  money. So, so that's one.
• 30:26
  So #2 is Jason Huang, of course, now he is the CEO for over 30
• 30:32
  years for NVIDIA. NVIDIA is really transforming
• 30:37
  the AI industry with their chips, right?
• 30:40
  So, but as you know, he also came from humble beginning.
• 30:44
  Of course he's, he's Asian. So I'm, I'm Asian and he is
• 30:48
  immigrant. I'm, I'm also immigrant.
• 30:50
  And really, you know, if you look at his stock price, I think
• 30:55
  you know, 20 years ago it was $0.04 for like 10 years or 20
• 30:59
  years, you know, so, so really, and he always called his team,
• 31:03
  he said we are 30 days away from bankruptcy.
• 31:06
  You guys just need to hurry, right?
• 31:09
  But even with all the tightness of funds and he went for the
• 31:14
  biggest right, he he went for something which basic
• 31:17
  transformed the whole whole field.
• 31:20
  So so that's and then when he gave a talk at the Stanford, he
• 31:26
  told the student, I wish you suffering because suffering
• 31:29
  actually builds character. So I that also gave me
• 31:33
  perspective is where we suffer. So probably we are, you know,
• 31:37
  digging in and and really drive the, you know, best out of us,
• 31:41
  right? So, so that give us, you know,
• 31:43
  good perspective. So that's number two and #3 is
• 31:48
  Michael Bloomberg. So as you know, he's in his 80s.
• 31:52
  He was three times. So for her mayor in New York,
• 31:55
  which you know, made New York to in to be in the black again, you
• 31:59
  know, and he's a Bloomberg Terminal is really transforming
• 32:03
  the industry. But as you know, you know, he he
• 32:06
  really started the Bloomberg Terminal this business when he
• 32:11
  was 39, when when his company, Solomon Brothers was a part
• 32:16
  right. So at 39 in this age in 1981, to
• 32:22
  start a company from scratch takes a lot of initiative and
• 32:26
  the courage and and the pay base is putting all his money, 10
• 32:32
  million from his severance from Salomon brother into the
• 32:35
  business and brought in, you know, Merrill Lynch to be the
• 32:38
  investor really made this into indispensable, you know, tool
• 32:45
  for all the you know, for the financial industry and really
• 32:48
  gave them, you know, the data and the decision making power in
• 32:52
  real time, right. So, so all of them actually are
• 32:55
  bringing a transforming a positive impact to the society
• 33:00
  and human lives. But if I give it one more twist,
• 33:04
  I just say, if I bring them to my dinner, what should we talk
• 33:08
  about? So I want to leave you with
• 33:11
  something we want to talk about. So you know, I have I have
• 33:18
  encountered this quote from Mother Teresa, so who I
• 33:23
  tremendously respect, right. So she represent the true human
• 33:27
  spirit. So let me read to you what she
• 33:30
  said and this is something we're we're going to discuss to start,
• 33:36
  Let me let me just read it to you.
• 33:40
  People are often unreasonable and self-centered.
• 33:44
  Forgive them anyway. If you're kind, people may
• 33:49
  accuse you of material motive. Be kind anyway.
• 33:56
  If you are honest, people may cheat you.
• 34:00
  Be honest anyway. If you find happiness, people
• 34:06
  may be jealous. Be happy anyway.
• 34:10
  The good you do today may be forgotten tomorrow.
• 34:15
  Do good. Give the world the best you have
• 34:20
  and it may never be enough. Give your best and for you see,
• 34:28
  in the end it's between you and God.
• 34:32
  It was never between you and them anyway.
• 34:36
  I love, I love all of the thought that went into that as
• 34:39
  well. I think there were really three
• 34:40
  amazing answers there. So yeah, that really enjoyed
• 34:44
  just listening to those answers actually.
• 34:46
  So look, it was an absolute pleasure LAN to have you on and
• 34:50
  thanks for coming on and helping us out of this.
• 34:52
  It sounds super exciting. What you you building seeds?
• 34:56
  I know it's a very exciting and hot field in CPD at the moment.
• 34:59
  So yeah, I'm looking forward to seeing the next milestones over
• 35:02
  the next year, year or two years.
• 35:05
  And yeah, congratulations on everything you building.
• 35:08
  It sounds super exciting. So yeah, thank you again.
• 35:11
  Thank you. So I I'm just very honored and
• 35:14
  grateful to our Co founders. You know, also, so including
• 35:18
  Lily and ASI, our investors and also our management team who
• 35:24
  have brought 12 drugs to NDA to really build a seed together.
• 35:30
  It's a journey together, it's a meaningful journey.
• 35:33
  And if we succeed, a patience and mankind will benefit.
• 35:37
  Amazing. Well, LAN, it was a it was a
• 35:39
  pleasure. Thanks again.
• 35:41
  Thank you.